F.M. Djuraev

8 ta ish

Oncology Tashkent Medical Park, Tashkent, Uzbekistan

28P One-week ultra-hypofractionated partial breast RT in early breast cancer: 3DCRT vs IMRT
N.O. Zaynutdinov, A.S. Abdujapparov, F.M. Djuraev +1
MaqolaMedical Imaging Techniques and ApplicationsAnnals of Oncology20230 iqtibos
ABI
10P Neoadjuvant chemotherapy with bevacizumab for IIb stage cervical cancer: Is it time to rethink standard of care?
F.M. Djuraev, A.S. Abdujapparov
MaqolaEndometrial and Cervical Cancer TreatmentsESMO Open20230 iqtibos
ABI
35P Beyond microsatellite testing: Tumor mutational burden, should it be routine in patients with GI cancers?
F.M. Djuraev, A.S. Abdujapparov
MaqolaGenetic factors in colorectal cancerESMO Open20240 iqtibos
ABI
30P Cemiplimab in treatment of metastatic and recurrent cervical cancer
F.M. Djuraev, A.S. Abdujapparov
MaqolaCancer Immunotherapy and BiomarkersESMO Open20240 iqtibos
ABI
19P Adjuvant chemotherapy in colon cancer: 6 months better than 3?
Z. Alisher, F.M. Djuraev, A.S. Abdujapparov
MaqolaColorectal Cancer Surgical TreatmentsAnnals of Oncology20240 iqtibos
ABI
265P Is it time to change standard care for dMMR locally advanced rectal cancer?
A.S. Abdujapparov, F.M. Djuraev
MaqolaColorectal Cancer Surgical TreatmentsAnnals of Oncology20240 iqtibos
ABI
IUC23223-77 Triplet therapy in metastatic hormone-sensitive prostate cancer in Asian patients
Alexey R. Zakirov, F.M. Djuraev, O Raxmonov +1
MaqolaProstate Cancer Treatment and ResearchThe Oncologist20250 iqtibos
ABI
63P Combination of pembrolizumab lenvatinib in treatment of advanced hepatocellular carcinoma
Z. Alisher, F.M. Djuraev
MaqolaHepatocellular Carcinoma Treatment and PrognosisESMO Open20260 iqtibos
ABI